No profile data available.
Silo Pharma, Inc. (SILO) is a healthcare company in the brain and nerve treatment drugs industry, based in Sarasota, United States, with about 3 full-time employees.
It reported revenue of $72,102 for fiscal year 2025, about flat from fiscal year 2024, and net income of -$4.23 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $18,026, about flat from a year before. Its market capitalization was $6.01 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
Silo Pharma reported $72,102 in revenue for fiscal year 2025, about flat from $72,102 in fiscal year 2024. In Q1 2026 revenue was $18,026.
$6.01 million as of December 4, 2025.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Reviva Pharmaceuticals Holdings, Inc. (RVPH), Enveric Biosciences, Inc. (ENVB), Alzamend Neuro, Inc. (ALZN), Jupiter Neurosciences, Inc. (JUNS).